DGAP-Adhoc: PAION AG GRANTS LICENSE TO HANA PHARM FOR REMIMAZOLAM IN SOUTH KOREA

PAION AG / Key word(s): Contract

28.10.2013 13:30

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PAION AG GRANTS LICENSE TO HANA PHARM FOR REMIMAZOLAM IN SOUTH KOREA

- PAION receives EUR 1 million upfront payment

- Potential milestone payments of up to EUR 2 million

- 10% royalties

Aachen (Germany), 28 October 2013 - PAION AG (ISIN DE000A0B65S3; Frankfurt
Stock Exchange General Standard: PA8) and Hana Pharmaceutical Co., Ltd,
South Korea, today announced that they have entered into a license
agreement for Remimazolam which gives Hana Pharm an exclusive licence for
the development, manufacture and commercialization in the territory of
South Korea.

By concluding the license PAION receives upfront payments totalling EUR 1
million. These consist of payment for the option in the amount of EUR 0.3
million (received in July 2013), and EUR 0.7 million are due by today's
signing of the license agreement. In addition, potential milestone payments
of up to EUR 2 million and 10% royalties on sales in the South Korean
market have been agreed.

Hana Pharm will manage and finance the development and marketing approval
process in South Korea. Hana Pharm intends to market Remimazolam in all
indications with the lead indication anaesthesia.

###

Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com

Disclaimer:
This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties and other
factors involved, recipients should not rely unreasonably upon these
forward-looking statements. PAION AG has no obligation to periodically
update any such forward-looking statements to reflect future events or
developments.

---------------------------------------------------------------------------

Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Germany
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: info@paion.com
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulierter Markt in Frankfurt (General Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------